



HAL
open science

Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more.

Jonathan D. Turner, Simone R. Alt, Lei Cao, Sara Vernocchi, Slavena Trifonova, Nadia Battello, Claude P. Muller

► **To cite this version:**

Jonathan D. Turner, Simone R. Alt, Lei Cao, Sara Vernocchi, Slavena Trifonova, et al.. Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more.. *Biochemical Pharmacology*, 2010, 80 (12), pp.1860. 10.1016/j.bcp.2010.06.037 . hal-00637161

HAL Id: hal-00637161

<https://hal.science/hal-00637161>

Submitted on 31 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Transcriptional control of the glucocorticoid receptor:
CpG islands, epigenetics and more.

Authors: Jonathan D. Turner, Simone R. Alt, Lei Cao, Sara Vernocchi, Slavena Trifonova, Nadia Battello, Claude P. Muller



PII: S0006-2952(10)00471-5
DOI: doi:10.1016/j.bcp.2010.06.037
Reference: BCP 10618

To appear in: *BCP*

Received date: 4-5-2010
Revised date: 18-6-2010
Accepted date: 21-6-2010

Please cite this article as: Turner JD, Alt SR, Cao L, Vernocchi S, Trifonova S, Battello N, Muller CP, Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more., *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.06.037

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 GR Transcription
2
3
45 1 Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more.
6
78 2
910 3 Jonathan D. Turner^{1,2}, Simone R. Alt^{1,2}, Lei Cao^{1,2}, Sara Vernocchi^{1,2}, Slavena
11
12 4 Trifonova^{1,2}, Nadia Battello¹, Claude P. Muller^{1,2}
13
14
1516 5
17
1819 6 ¹Institute of Immunology, CRP-Santé / Laboratoire National de Santé, 20A rue Auguste
20
21
22 7 Lumière, L-1950, Luxembourg
23
2425 8 ²Department of Immunology, Graduate School of Psychobiology, University of
26
27
28 9 Trier, D-54290, Germany
2930 10
31
3233 11
34
3536 12
37
3839 13 Running title: GR transcription
40
4142 14
43
4445 15
46
4748 16 Address for correspondence:
4950 17 Claude P. Muller, Institute of Immunology, CRP-Santé/Laboratoire National de Santé,
51
52 18 20A rue Auguste Lumière, L-1950 Grand Duchy of Luxembourg.
5354 19 Tel: +352 490604 Fax: +352 490686
5556 20 Email: claude.muller@LNS.ETAT.LU
57
58
59
60
61
62
63
64
65

GR Transcription

Abstract

The unique variability in the 5' region of the GR gene, with 9 alternative first exons and 13 splice variants plays a critical role in transcriptional control maintaining homeostasis of the glucocorticoid receptor (GR). This 5'mRNA heterogeneity, common to all species investigated, remains untranslated since the alternative first exons are spliced to exon 2 immediately upstream of the translation initiation codon. These alternative first exons are located either immediately upstream of the coding exons in the CpG island (exons B-H and J), or further upstream (exons 1A and 1I). The mechanisms regulating the differential usage of these first exons in different tissues and individuals, and the role of the 5'UTR in the splicing of the coding exons are still poorly understood. Here we review some of the mechanisms that have so far been identified. Data from our laboratory and others have shown that the multiple first exons represent only a first layer of complexity orchestrated probably by tissue-specific transcription factors. Modulation of alternative first exon activity by epigenetic methylation of their promoters represents a second layer of complexity at least partially controlled by perinatal programming. The alternative promoter usage also appears to affect the 3' splicing generating the different GR coding variants, GR α , GR β , and GR-P. Aberrant GR levels are associated with stress-related disorders such as depression, and affect social behaviour, mood, learning and memory. Dissecting how tissue-specific GR levels are regulated, in particular in the brain, is a first step to understand the significance of aberrant GR levels in disease and behaviour.

Keywords: Glucocorticoid receptor; Promoter; Methylation; Epigenetic variability; alternative exon splicing

1 GR Transcription
2
3

4 **1 Introduction**

5
6 2 Stress causes an increasing disease burden at least in Western societies. Economic losses
7
8 3 due to stress may be as high as 3-4% of the European gross national product. In addition,
9
10 4 stress has detrimental effects on behaviour, mood, learning and memory that are difficult
11
12 5 to quantify. Glucocorticoids (GCs), the key stress mediators, exert profound effects on a
13
14 6 wide range of physiological and developmental processes that are crucial for the
15
16 7 adaptation to stress. Psychosocial stress has also been implicated in the development of
17
18 8 mental disorders, including schizophrenia, anxiety disorders, and depression.
19
20
21

22
23 9 GCs act via binding to two types of intracellular nuclear receptors, i.e. the glucocorticoid
24
25 10 receptor (GR) and the mineralocorticoid receptor (MR). Upon binding of GCs, these
26
27 11 receptors translocate to the nucleus where they regulate the activity of specific target
28
29 12 genes, in a cell-type specific manner, as transcription factors. This review focuses on the
30
31 13 classical GR, NR3C1. Numerous factors have been demonstrated to affect the
32
33 14 responsiveness to GC by regulating GR activity, such as GR co-activators and co-
34
35 15 repressors [1], GR splice-variants [2-4], and GR isoforms [5-7]. In addition, and perhaps
36
37 16 most important for GC responsiveness is the expression level of GR protein [8-11],
38
39 17 determined by the mRNA level.
40
41
42
43
44

45 18 In eukaryotic cells, gene expression is controlled by a variety of mechanisms, both at
46
47 19 transcriptional and translational levels, including chromatin condensation, transcription
48
49 20 initiation, DNA methylation, alternative RNA splicing, mRNA stability and others. The
50
51 21 GR is an ubiquitously expressed nuclear hormone receptor, however, levels of both
52
53 22 mRNA and protein vary widely between cell and tissue types. Over the last few years we
54
55 23 and others have contributed to the significant progress that has been made to unravel the
56
57
58
59
60
61
62
63
64
65

GR Transcription

transcriptional mechanisms determining the tissue specific control of GR levels, that will be reviewed here.

Structure of the NR3C1 gene

The human GR gene (OMIM + 138040; NR3C1) is located on chromosome 5q31-q32 [12] and contains 8 translated exons (2-9) and 9 untranslated alternative first exons. We and others have shown that GR levels are under the transcriptional control of a complex 5' structure of the gene, containing the untranslated first exons important for differential expression of the GR. All of the alternative first exons identified are located in one of the two promoter regions: the proximal or the distal promoter region, located approximately 5kb and 30kb upstream of the translation start site, respectively [13-18]. Alternative first exons 1A, and 1I are under the control of promoters in the distal promoter region, whereas the promoters of exons 1D, 1J, 1E, 1B, 1F, 1C (1C1-3), 1H (Fig. 1A) are located in the proximal promoter region [19, 20]. Exons 1D to 1H are found in an upstream CpG island with a high sequence homology between rats and humans.

The region- or tissue-specific usage of alternative first exons leading to different GR mRNA transcripts [19, 20] (Fig. 1 B) provides a mechanism for the local fine-tuning of GR levels. Since the ATG start codon lies only in the common exon 2, this 5'mRNA heterogeneity remains untranslated, but is important for translational regulation [21].

Alternative mRNA transcript variants are generated by splicing of these alternative first exons to a common acceptor site in the second exon of the GR. Exon 2 contains an in-frame stop codon immediately upstream of the ATG start codon to ensure that this 5'

GR Transcription

1 heterogeneity remains untranslated, and that the sequence and structure of the GR is not
2 affected.

3 The GR also has a variable 3' region. Unlike the 5' region, the 3' variability encodes
4 splice variants with different functions. The 3 main 3' splice variants of the GR are GR α ,
5 GR β , and GR-P (Fig. 1B). GR α and GR β are generated by two alternatively spliced 3'
6 exons, 9 α and 9 β . GR-P lacks both exons 8 and 9 and is translated into a protein with a
7 truncated ligand binding domain (LBD) which is thought to enhance GR α activity. GR α
8 is by far the most active form of the receptor, GR β is thought to be a dominant negative
9 regulator of the receptor, and little is known about the function of GR-P.

11 **Alternative first exon usage and 3' splice variants**

12 The recent observation that transcription factors binding to pol II transcribed promoters
13 modulate alternative splicing, supports a physical and functional link between
14 transcription and splicing [22]. Several factors were identified that were critical for the
15 recruitment of a specific set of co-regulators to pol II transcribed gene promoters and the
16 production of a specific splice variants. The splice variant produced depends on the
17 structural organisation of the gene and the nature of the co-regulators involved [23]. A
18 link between transcription initiation sites and the resulting splice variant was suggested
19 since it was shown that promoters controlled alternative splicing also via the regulation of
20 pol II elongation rates or processivity. Slow pol II elongation paired with internal
21 elongation pauses favoured the inclusion of alternative exons governed by an exon
22 skipping mechanism, whereas high elongation rates of pol II, without internal pauses
23 favoured the exclusion of such exons.

GR Transcription

1 Many eukaryotic genes contain multiple promoters that are alternatively used for the
2 production of different protein isoforms, with important physiological consequences.
3 However, the GR with its variable 5' UTR, and alternative splicing in the 3' coding
4 region is unique. Little is known about the association between the promoter usage and
5 the resulting GR protein isoform. The 5' UTR has tight control over local GR expression
6 levels. There seems to be also a poorly understood statistical link between the 5'UTR and
7 3' splice variants produced. One of the first studies to address this question showed that
8 exon 1A3, and to a lesser extend 1B and 1C contribute most to the expression of GR- α
9 isoform [24]. By comparing the most abundant exon 1 containing transcripts (1A, 1B 1C)
10 with GR α , GR β , and GR-P containing transcripts in different tissues and cell lines,
11 Russcher *et al.* found a correlation between promoter usage and alternative splicing of the
12 GR gene [25]. More specifically they found that the expression of GR α is preferentially
13 regulated by promoter 1C, whereas 1B usage favours the expression of GR-P isoform. No
14 association was found with transcripts including exon 9 β or with those transcribed from
15 1A, suggesting that GR β splicing may be associated with one of the recently identified
16 exon 1 variants such as 1D to 1F and 1H that were not included in the above study [25].
17 We also confirmed that in post-mortem brain tissues of patients with major depressive
18 disorder (MDD) altered promoter usage influenced the resulting 3'GR isoform, with a
19 negative correlation between GR-P expression and promoter 1B usage in all brain areas
20 of MDD patients but not in normal control brains. A negative correlation was also found
21 between the 1C promoter usage and GR-P expression in MDD brains. These results
22 suggest that the promoters 1B or 1C do not play a significant role in GR-P expression in
23 MDD, and that they were rather linked to other forms with lower expression [26]. Thus,

GR Transcription

1 current data suggest a link between the two ends of the mRNA transcript, but there is no
2 consensus as to the nature of this link.

3

4 **Transcription factors and transcriptional control within the CpG island**

5 The hGR was initially described as a housekeeping or constitutively expressed gene with
6 promoters that contain multiple GC boxes and no TATA or TATA-like box [27]. A wide
7 variety of transcription factors have been identified that bind in the CpG island upstream
8 of the gene. The description of the transcription factors active within this region is
9 complicated by their tissue-specific usage. These transcription factors were not assigned
10 to the different exon 1 promoters since most of this work was performed before our
11 detailed description of the first exons in this region. The transcription factors so far
12 identified are summarised (Table 1) and their location within the CpG island shown in
13 Figure 1C. Initially, 11 DNase 1 footprints representing unique transcription factor
14 binding sites were found in the 1C to 1F region of the CpG island (-3259 to -2522 from
15 the ATG start codon) including, one AP-2 and 5 Sp-1 binding sites were identified [28].
16 It was initially thought that the latter transcription factors played an essential role in the
17 basal expression of the hGR, although this is now less clear. Further studies identified
18 one of the footprints in promoter 1C as a binding site for the transcription factor Yin
19 Yang 1 [15]. YY1, expressed in a wide variety of mammalian cell types, is a zinc-finger
20 transcription factor that can act as an activator, a repressor, or an initiator of transcription
21 [17, 29]. The same authors also revealed three other YY1 sites and another Sp1 site,
22 initially assigned to promoter 1B. The later identification of promoter 1D suggested that

GR Transcription

1 these YY1 sites are probably associated with this promoter [30]. Similarly, the Sp1 sites
2 correspond to a region that was later identified as promoter 1J [20].
3 Similarly, several transcription factors initially assigned to promoter 1C should be
4 reassigned to promoter 1F. AP-1, a transcription complex whose components are encoded
5 by c-fos and c-jun proto-oncogenes binds to the AP-1 site within the hGR promoter 1F
6 [14, 31]. This same region was also shown to bind Ku70 and Ku 80 in a tissue-specific
7 manner [32]. Whilst most of the transcription factors identified upregulate GR
8 expression, GRF-1 (glucocorticoid receptor DNA binding factor 1) has been identified as
9 a repressor of GR transcription [33, 34]. At the 3' end of the rat 1₇ promoter a NGFI-A
10 binding site was identified only 2 bp upstream of the transcription initiation site of this
11 exon [35]. Recently, the homologous human NGFI-A binding site, together with
12 numerous non-canonical NGFI-A sites were identified in promoter 1F of the hGR [36].
13 As a transcription factor, GR also auto-regulates its own CpG island promoters. Several
14 glucocorticoid response element (GRE) half-sites, acting in concert with c-Myb, and c-
15 Ets protein members have been identified in promoter 1D, 1E, 1F and 1C [37].
16 The currently known transcription factors provide only an incomplete picture of the
17 complex regulatory mechanisms. For instance, little is known about the proximal
18 elements in promoters 1B and 1H. Using an *in silico* phylogenetic footprinting technique
19 we were able to find the majority of the experimentally identified transcription factors,
20 and predicted a wide variety of factors that are conserved between many species [38].
21 These are interesting candidate regulators of GR expression that warrant further
22 investigations.

GR Transcription

1 It has not yet been shown whether the transcription factors that bind immediately
2 upstream of exons D, E, F, H, and I, activate the expression of these exons. Only site 13,
3 one of 6 in the region immediately upstream of exon 1F (Fig. 1C), has been shown to
4 activate transcription of the downstream exon. Furthermore, the link between the
5 transcription factors previously identified, or predicted, and the transcription of the new
6 CpG island first exons must be established.

8 **Transcriptional control upstream of the CpG island: Exon 1A and 1I**

9 Whilst the majority of the GR first exons and their promoters are located within the CpG
10 island, exons 1A and 1I map 25 Kb upstream of the CpG island and 32 Kb upstream of
11 the main GR ORF in the distal promoter region [16, 20]. Exon 1A has also been
12 identified in the mouse, and three possible homologues 1₁, 1₂, and 1₃ have been found in
13 the rat [39, 40]. The human promoter 1A generates 3 alternatively spliced transcripts,
14 1A1, 1A2 and 1A3 [16]. Expression of the 1A transcripts appears to be limited to the
15 immune system in both humans and rodents. The human 1A3 transcript is widely
16 expressed in both acute lymphoblastic leukemia (ALL) cell lines and in children with this
17 malignancy [16, 20, 25, 41-43]. Similarly, exon 1I is used predominantly in T cells,
18 although it is also present in HeLa cells [20].

19 Promoter 1A is regulated by the GR itself. The human 1A promoter contains a GC-
20 responsive cassette containing a non-canonical GRE adjacent to overlapping binding sites
21 for c-Myb and c-Ets protein family members. In the presence of c-Myb the ligand-bound
22 GR is recruited to the promoter and up-regulates 1A transcripts, while the interaction
23 with c-Ets family members leads to a repression of 1A promoter activity [18, 44]. This

GR Transcription

1 explains in part the opposite effects observed in different tissues: in most tissues GC
2 decreases GR expression, but in and certain T cells GCs increase GR expression. The
3 synergy between c-Ets and the GR has been shown to be responsible for the down
4 regulation of 1A3 in the B lymphoblastoid cell line IM-9 after GC exposure. In contrast,
5 the presence of c-Myb in T cells increased the activity of promoter 1A in human cell lines
6 such as the ALL T cell line CEM-C7. As a result of the higher level of total GR T cells
7 are more sensitive to GC induced apoptosis, and 1A3- transcripts were shown to be the
8 most GC responsive of all first exons investigated [16, 24]. Although 1A containing
9 transcripts correspond to only about 10% of all GR transcripts [42], their contribution to
10 the tissue-specific response to GC treatment was considered essential [16, 24]. The
11 human promoter 1A also has a functional binding site for Interferon Regulatory Factors
12 (IRF-1 and IRF-2), however IFN γ stimulation of CEM-C7 cells did not increase 1A
13 transcript levels, nor did it alter their susceptibility to GC-mediated apoptosis [45].
14 Thus the evidence suggests that 1A transcript levels are critically involved in mechanisms
15 of therapeutic induction of apoptosis in ALL T cells. However, GC resistance in pediatric
16 T- and B- ALL cells obtained directly from patients did not correlate with either the basal
17 or the stimulated expression of the 1A-, 1B- or 1C- transcripts. The relation between GC
18 sensitivity and expression of GR transcripts may be complicated by the overlapping
19 effects such as multi drug resistance genes that prevent GC concentrations from building
20 up in the cells. In addition, ALL cells were shown to have an up-regulated GR expression
21 upon prednisolone treatment regardless of their phenotype or sensitivity to GC-induced
22 apoptosis [42].

GR Transcription

1 In mice the presence of the membrane-bound GR was a better correlate of GC-induced
2 apoptosis than the intracellular GR level [46, 47]. Exon 1A was found to be highly
3 expressed in a T lymphoma cell line with elevated levels of membrane-bound GR and
4 enhanced sensitivity to GC-dependent cytotoxicity. 1A transcripts appear to contain all
5 the necessary information for both the synthesis and the subcellular trafficking of the
6 membrane GR, although the exact mechanism remains unknown [41]. It is interesting to
7 hypothesise that the initially presumed link between GC induced apoptosis and 1A
8 transcript levels is indirect, with 1A transcripts producing membrane GR the true
9 correlate of GC sensitivity. Recently a similar membrane GR has been detected in human
10 cells, but its sequence is not known [48, 49]. The membrane GR may eventually explain
11 the discrepancy between the *in vivo* and *in vitro* observations in ALL. It is interesting to
12 speculate that, as in the mouse, the different first exons determine the cellular fate of the
13 human GR.

14 Further sequence analysis of mouse exon 1A found 5 small upstream-ORFs preceding the
15 major ORF of the GR. It has been shown that GR expression from the 1A transcript
16 requires translation of the peptide encoded by uORF-2. The peptide was detectable in
17 both cells with naturally 1A transcripts and cells transfected with 1A. The role of this
18 peptide in the regulation of the membrane GR is still unclear [50].

20 Epigenetic programming of GR promoters

21 Epigenetic methylation of the 5'-cytosine of a CpG dinucleotide is associated with gene
22 silencing either by inhibition of transcription factor binding (Fig. 2) or by chromatin
23 inactivation [51-53]. For instance, prenatal epigenetic methylation governs genomic

GR Transcription

1 imprinting and inactivation of one X-chromosome [54]. The epigenetic chromatin status
2 is sensitive to the host environment. Thus, epigenetic methylation represents a link
3 between the environment and gene activity. In particular, early life events can have a
4 long-lasting effect on epigenetic programming [52, 53]. In many instances, minor
5 changes in GR levels can have a significant impact, for example on feedback regulation
6 of the HPA axis, where hippocampal or pituitary GR levels determine the HPA axis set-
7 points and the response to stress.

8 Experimentally, maternal care such as licking-grooming (LG) and arched-back nursing
9 (ABN) has been shown to translate into epigenetic methylation of the GR promoter 1₇
10 with profound and lasting effects on the stress response of the off-springs. [55]. The
11 NGFI-A binding site in the GR promoter 1₇ (Fig. 3), homologous to the human 1F, was
12 highly methylated (>80%) in the offspring of low caring mothers whereas it was rarely
13 methylated in the offspring of high caring rats [35]. As a result, binding of NGFI-A to the
14 GR 1₇ promoter was inhibited in the hippocampus of offspring of low caring mothers and
15 GR 1₇ expression was reduced [56]. Interestingly, these effects were reversed by cross-
16 fostering indicating a direct effect of maternal care on the epigenome of the offspring
17 [35]. Infusion of L-methionine reversed these effects on methylation and NGFI-A
18 binding to the exon 1₇ promoter in the rat brain [57].

19 In Lewis and Fisher rats that naturally differ in their stress response and hippocampal GR
20 levels, the 1₇ promoter was shown to be un- or poorly methylated throughout (mostly
21 below 10% and never exceeding 30%), with no difference between the two strains.
22 Feeding these rats a methyl-supplemented diet had no significant effect on the GR
23 promoter 1₇ methylation levels [58].

GR Transcription

1 Using the maternal separation model to change the stress response in rat pups (Table 2),
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Using the maternal separation model to change the stress response in rat pups (Table 2),
2 Daniels *et al.* observed elevated NGFI-A levels and significant behavioural changes. In
3 this model, the 1₇ promoter, including both CpG sites within the NGFI-A binding site,
4 was uniformly un-methylated even after applying the maternal separation stressor [59].
5 Epigenetic programming of the GR is not limited to central tissues such as the
6 hippocampus. It has also been proposed that dietary restriction could lead to changes in
7 DNA methyl content, affecting epigenetic programming of the GR promoter both
8 centrally and peripherally [60]. Feeding a protein-restricted diet to pregnant dams lead to
9 a hypomethylation of the major GR promoter 1₁₀ and to an increased expression of GR in
10 the liver of these rat pups [61].
11 These animal models showing changes in GR promoter methylation are not easily
12 transferred to humans. Nevertheless maternal adversities like depression or protein
13 restriction and their effects on the epigenome of offspring have been investigated (Table
14 2). Oberlander *et al.* showed that prenatal exposure to maternal depression leads to
15 increased methylation levels of the GR promoter 1F at the NGFI-A binding site in cord
16 blood of newborns [62]. Like in most rat experiments, methylation levels were uniformly
17 low (5-10 %) with small but significant differences between children of depressed and
18 healthy mothers.
19 Several studies also investigated alterations in the human GR 1F promoter in specific
20 disease populations based on the rat 1₇ data of Weaver *et al.* [35]. In neurological
21 disorders such as Parkinson's disease, Alzheimer's or dementia no hypermethylation of
22 the 1F promoter and the NGFI-A binding site could be found [63]. We showed that in
23 major depressive disorder there was no methylation of the NGFI-A binding site of the 1F

GR Transcription

1 promoter in several regions of human post-mortem brains [26]. However, in suicide
2 victims with a history of child abuse, McGowan *et al.* found increased methylation
3 patterns compared to suicide victims without abuse [36]. In this study, methylation of
4 another putative NGFI-A binding site within promoter 1F resulted in decreased
5 expression levels of 1F transcripts and overall GR levels. The known NGFI-A binding
6 site was completely unmethylated in all of the suicide victims. Thus, it is possible that
7 other transcription factor binding sites are important for the transcriptional regulation of
8 the GR 1F promoter and that these are more sensitive to epigenetic modifications.
9 Interestingly, in all four of the above studies [26, 36, 62, 63], levels of methylation were
10 always very low in comparison to those in the LG-ABN rats [35]. Investigating the
11 complete GR CpG island, we were able to show highly variable methylation patterns
12 among different GR promoters in PBMC's of healthy donors, suggesting that epigenetic
13 programming may not be restricted to the 1F promoter, but operates throughout the CpG
14 island [33]. It remains unclear, however, what triggers changes in methylation, and when
15 are the different tissues most susceptible to epigenetic programming. Despite some
16 contradictions it seems that levels of methylation are consistently low in the brain, and
17 somewhat higher and more variable at least in the blood mononuclear cells and liver.

19 The future - GR post-transcriptional regulation by miRNAs?

20 MicroRNAs (miRNAs) were discovered in 2001 [64, 65]. In mammalian, miRNAs were
21 predicted to regulate up to 30% of all genes [66]. So far they have been shown to be
22 involved in almost every cellular process investigated [67, 68]. It is now recognised that
23 miRNAs account for about 1% of the human genome and that they play a key role in

GR Transcription

1 many regulatory pathways such as development timing, cell differentiation and apoptosis
2 [69]. MicroRNAs are single-stranded RNA molecules of about 21 nucleotides in length
3 that bind through imperfect base pairing to their target mRNAs, interfering with
4 translational output [70]. miRNAs can either be encoded within an intronic locus [71, 72]
5 or they cluster within intergenic regions [73]. miRNA gene transcription gives a primary
6 miRNA transcript (pri-miRNA) that after subsequent processing (reviewed in [74]) is
7 incorporated into the RNA Induced Silencing Complex (RISC). The seed region, a 6-8
8 nucleotide long sequence situated at the 5' end of the miRNA, nucleates the binding of
9 miRNAs to their mRNA targets, requiring several contiguous and perfect by matching
10 base pairs [75]. With a few exceptions, miRNA-binding sites in metazoan mRNA lie in
11 the 3'UTR of the target gene and are usually present in multiple copies [76-80]. The
12 exact mechanisms by which miRNAs repress translation remain unclear. However, it is
13 known that miRNAs not only induce mRNA deadenylation and degradation but they also
14 seem to interfere with protein synthesis [81].

15 There is now evidence that miRNAs are involved in the regulation of hippocampal GR
16 levels modulating the HPA axis responsiveness [82]. The 3' UTR of the GR was
17 predicted to contain numerous seed regions recognized by a variety of miRNAs two of
18 which were miR-18 and miR-124a [83]. Both reduced GR protein levels and the overall
19 GR activities measured by target gene expression levels. miR-18 inhibited GR mRNA
20 translation in cultured neuronal cells and was shown to be up-regulated in the
21 paraventricular nucleus of Fischer 344 rats, a strain hypersensitive to stress. Interestingly,
22 it has been known for some time that Fischer 344 rats have low GR levels in the
23 hippocampus compared to Lewis rats. Together, these results suggest a role of miR-18 in

GR Transcription

1 GR down-regulation, increasing the vulnerability to repeated stress [84]. In contrast to
2 miR-18, which was expressed in numerous tissues, miR-124a expression was restricted to
3 certain brain regions and changed during the stress neonatal hyporesponsive period [85].
4 Little is known about miRNA targeting 5'UTRs, although target sites for endogenous
5 miRNAs can also be identified in these upstream gene regions. A recent study reported
6 mRNAs to be repressed as efficiently by miRNA binding in the 5' as in the 3' UTR
7 although previously 5' miRNAs were shown to be less effective than those binding in the
8 3'UTRs [86]. Most surprisingly, by binding to the 5'UTR, miRNA family member miR-
9 10 enhanced the translation of its target mRNA [87].
10 Nothing is known so far about miRNAs targeting the 5' UTR of GR mRNAs.
11 Considering the high variability of the GR 5'UTRs and tissue-dependent first exon usage
12 [19, 30], it is attractive to hypothesise that miRNAs may add yet another layer of
13 transcriptional complexity to the GR. Using the online version of PITA (Probability of
14 Interaction by Target Accessibility) [88], we predicted a number of highly significant
15 miRNA binding sites within the GR first exon Figure (4). To determine if and how these
16 miRNAs are involved in GR posttranscriptional regulation remains a rewarding
17 challenge.

Summary

18
19
20 The studies presented in this review demonstrate the multiple layers of complexity
21 involved in the maintenance of the homeostasis of the ubiquitously expressed GR. Data
22 from our laboratory and others have shown that the multiple first exons represent a first
23 layer of complexity playing a particular role in tissue-specific transcriptional regulation.

GR Transcription

1 The abundance of the alternative exons is modulated by epigenetic methylation of their
2 promoters. Finally, we suggest that the mature mRNA will be susceptible to miRNA
3 effects that are transcript specific. Whilst the amount of the GR is thought to be the main
4 determinant of the GC response, the third layer of complexity, beyond the scope of this
5 review is the interaction of the mature GR with its numerous co-regulators and co-
6 repressor proteins, as well as their interactions with the other steroid receptors upon
7 ligation.

8
9 Amongst the many open questions is the effect of the alternative 5' transcripts on
10 translation. It is likely that the 5'UTR sequence will affect the recruitment of the
11 translational machinery, translation rates, as well as mRNA stability. Together these will
12 further regulate the amount of GR generated, the ultimate determinant of GC sensitivity.
13 Determining how these different mechanisms converge to produce an adequate stress
14 response in the healthy and the sick is one of the next major challenges.

15
16 When we published the structure of the GR 5'UTR its complexity was unique. However,
17 over the last few years an unexpected variability in the 5' UTR of genes throughout the
18 complete genome has unfolded. In 2001 there were only 2 human genes known to have
19 >10 first exons [89], in 2006 this had expanded to at least 43 [90]. Although there is no
20 more recent data, comprehensive analysis of the ENCODE project data suggests that
21 >20% of all human genes have multiple alternative promoters [91]. Data from the
22 Database of Transcription Start sites (DBTSS) even suggests that >50% of all genes have
23 alternative first exons and associated promoters [92]. The discrepancy between these two

GR Transcription

1 estimates is most probably due to the greater variety of tissue and cell types available in
2 the DBTSS, underscoring tissue specificity of these first exons. Thus, genes with
3 alternative first exons, translated or not, seem to be the rule rather than the exception as
4 initially thought for the GR.

5

6

7

GR Transcription

References:

- [1] Kumar R, Thompson EB. Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. *Mol Endocrinol* 2003;17:1-10.
- [2] DeRijk RH, Schaaf M, Stam FJ, de Jong IE, Swaab DF, Ravid R, et al. Very low levels of the glucocorticoid receptor beta isoform in the human hippocampus as shown by Taqman RT-PCR and immunocytochemistry. *Brain Res Mol Brain Res* 2003;116:17-26.
- [3] Derijk RH, Schaaf MJ, Turner G, Datson NA, Vreugdenhil E, Cidlowski J, et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. *J Rheumatol* 2001;28:2383-8.
- [4] Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. *J Steroid Biochem Mol Biol* 2002;83:37-48.
- [5] Lu NZ, Collins JB, Grissom SF, Cidlowski JA. Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. *Mol Cell Biol* 2007;27:7143-60.
- [6] Lu NZ, Cidlowski JA. Glucocorticoid receptor isoforms generate transcription specificity. *Trends Cell Biol* 2006;16:301-7.
- [7] Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. *Mol Cell* 2005;18:331-42.
- [8] Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. *Endocr Rev* 1996;17:245-61.
- [9] Reichardt HM, Umland T, Bauer A, Kretz O, Schutz G. Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. *Mol Cell Biol* 2000;20:9009-17.
- [10] Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W, et al. Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. *J Neurosci* 2005;25:6243-50.
- [11] van der Laan S, Lachize SB, Vreugdenhil E, de Kloet ER, Meijer OC. Nuclear receptor coregulators differentially modulate induction and glucocorticoid receptor-mediated repression of the corticotropin-releasing hormone gene. *Endocrinology* 2008;149:725-32.
- [12] Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. *Nature* 1985;318:635-41.
- [13] Barrett TJ, Vig E, Vedeckis WV. Coordinate regulation of glucocorticoid receptor and c-jun gene expression is cell type-specific and exhibits differential hormonal sensitivity for down- and up-regulation. *Biochemistry* 1996;35:9746-53.
- [14] Wei P, Vedeckis WV. Regulation of the glucocorticoid receptor gene by the AP-1 transcription factor. *Endocrine* 1997;7:303-10.
- [15] Breslin MB, Vedeckis WV. The human glucocorticoid receptor promoter upstream sequences contain binding sites for the ubiquitous transcription factor, Yin Yang 1. *J Steroid Biochem Mol Biol* 1998;67:369-81.

GR Transcription

- 1
2
3
4 [16] Breslin MB, Geng CD, Vedeckis WV. Multiple promoters exist in the human GR
5 gene, one of which is activated by glucocorticoids. *Mol Endocrinol*
6 2001;15:1381-95.
7
8 [17] Nunez BS, Vedeckis WV. Characterization of promoter 1B in the human
9 glucocorticoid receptor gene. *Mol Cell Endocrinol* 2002;189:191-9.
10 [18] Geng CD, Vedeckis WV. Steroid-responsive sequences in the human
11 glucocorticoid receptor gene 1A promoter. *Mol Endocrinol* 2004;18:912-24.
12 [19] Turner JD, Muller CP. Structure of the glucocorticoid receptor (NR3C1) gene 5'
13 untranslated region: identification, and tissue distribution of multiple new human
14 exon 1. *J Mol Endocrinol* 2005;35:283-92.
15 [20] Presul E, Schmidt S, Kofler R, Helmberg A. Identification, tissue expression, and
16 glucocorticoid responsiveness of alternative first exons of the human
17 glucocorticoid receptor. *J Mol Endocrinol* 2007;38:79-90.
18 [21] Pickering BM, Willis AE. The implications of structured 5' untranslated regions
19 on translation and disease. *Semin Cell Dev Biol* 2005;16:39-47.
20 [22] Kornblihtt AR. Promoter usage and alternative splicing. *Current opinion in Cell*
21 *Biology* 2005.
22 [23] Didier Auboeuf DHD, Yun Kyoung Kang. Differential recruitment of nuclear
24 receptor coactivators may determine alternative RNA splice site choice in target
25 genes. *PNAS* 2003;101.
26 [24] Pedersen KB, Vedeckis WV. Quantification and glucocorticoid regulation of
27 glucocorticoid receptor transcripts in two human leukemic cell lines.
28 *Biochemistry* 2003;42:10978-90.
29 [25] Russcher H, Dalm VA, de Jong FH, Brinkmann AO, Hofland LJ, Lamberts SW,
30 et al. Associations between promoter usage and alternative splicing of the
31 glucocorticoid receptor gene. *J Mol Endocrinol* 2007;38:91-8.
32 [26] Alt SR, Turner JD, Klok MD, Meijer OC, Lakke EA, Derijk RH, et al.
33 Differential expression of glucocorticoid receptor transcripts in major depressive
34 disorder is not epigenetically programmed. *Psychoneuroendocrinology*
35 2010;35:544-56.
36 [27] Zong J, Ashraf J, Thompson EB. The promoter and first, untranslated exon of the
37 human glucocorticoid receptor gene are GC rich but lack consensus
38 glucocorticoid receptor element sites. *Mol Cell Biol* 1990;10:5580-5.
39 [28] Nobukuni Y, Smith CL, Hager GL, Detera-Wadleigh SD. Characterization of the
40 human glucocorticoid receptor promoter. *Biochemistry* 1995;34:8207-14.
41 [29] Shrivastava A, Calame K. An analysis of genes regulated by the multi-functional
42 transcriptional regulator Yin Yang-1. *Nucleic Acids Res* 1994;22:5151-5.
43 [30] Turner JD, Schote AB, Macedo JA, Pelascini LP, Muller CP. Tissue specific
44 glucocorticoid receptor expression, a role for alternative first exon usage?
45 *Biochem Pharmacol* 2006;72:1529-37.
46 [31] Breslin MB, vedeckis WV. The Glucocorticoid Receptor and c-jun Promoters
47 Contain AP-1 Sites That Bind Different AP-1 Transcription factors. *Endocrine*
48 1996;5:15-22.
49 [32] Warriar N, Page N, Govindan MV. Expression of human glucocorticoid receptor
50 gene and interaction of nuclear proteins with the transcriptional control element. *J*
51 *Biol Chem* 1996;271:18662-71.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

GR Transcription

- 1
2
3
4 [33] LeClerc S, Palaniswami R, Xie BX, Govindan MV. Molecular cloning and
5 characterization of a factor that binds the human glucocorticoid receptor gene and
6 represses its expression. *J Biol Chem* 1991;266:17333-40.
7
8 [34] Leclerc S, Xie BX, Roy R, Govindan MV. Purification of a human glucocorticoid
9 receptor gene promoter-binding protein. Production of polyclonal antibodies
10 against the purified factor. *J Biol Chem* 1991;266:8711-9.
11
12 [35] Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al.
13 Epigenetic programming by maternal behavior. *Nat Neurosci* 2004;7:847-54.
14
15 [36] McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al.
16 Epigenetic regulation of the glucocorticoid receptor in human brain associates
17 with childhood abuse. *Nat Neurosci* 2009;12:342-8.
18
19 [37] Geng CD, Schwartz JR, Vedeckis WV. A conserved molecular mechanism is
20 responsible for the auto-up-regulation of glucocorticoid receptor gene promoters.
21 *Mol Endocrinol* 2008;22:2624-42.
22
23 [38] Turner JD, Pelascini LP, Macedo JA, Muller CP. Highly individual methylation
24 patterns of alternative glucocorticoid receptor promoters suggest individualized
25 epigenetic regulatory mechanisms. *Nucleic Acids Res* 2008;36:7207-18.
26
27 [39] Strahle U, Schmidt A, Kelsey G, Stewart AF, Cole TJ, Schmid W, et al. At least
28 three promoters direct expression of the mouse glucocorticoid receptor gene. *Proc*
29 *Natl Acad Sci U S A* 1992;89:6731-5.
30
31 [40] McCormick JA, Lyons V, Jacobson MD, Noble J, Diorio J, Nyirenda M, et al. 5'-
32 heterogeneity of glucocorticoid receptor messenger RNA is tissue specific:
33 differential regulation of variant transcripts by early-life events. *Mol Endocrinol*
34 2000;14:506-17.
35
36 [41] Chen F, Watson CS, Gametchu B. Association of the glucocorticoid receptor
37 alternatively-spliced transcript 1A with the presence of the high molecular weight
38 membrane glucocorticoid receptor in mouse lymphoma cells. *J Cell Biochem*
39 1999;74:430-46.
40
41 [42] Tissing WJ, Meijerink JP, Brinkhof B, Broekhuis MJ, Menezes RX, den Boer
42 ML, et al. Glucocorticoid-induced glucocorticoid receptor expression and
43 promoter-usage is not linked to glucocorticoid resistance in childhood ALL.
44 *Blood* 2006.
45
46 [43] Chen F, Watson CS, Gametchu B. Multiple glucocorticoid receptor transcripts in
47 membrane glucocorticoid receptor-enriched S-49 mouse lymphoma cells. *J Cell*
48 *Biochem* 1999;74:418-29.
49
50 [44] Geng CD, Pedersen KB, Nunez BS, Vedeckis WV. Human glucocorticoid
51 receptor alpha transcript splice variants with exon 2 deletions: evidence for tissue-
52 and cell type-specific functions. *Biochemistry* 2005;44:7395-405.
53
54 [45] Nunez BS, Geng CD, Pedersen KB, Millro-Macklin CD, Vedeckis WV.
55 Interaction between the Interferon Signaling Pathway and the Human
56 Glucocorticoid Receptor Gene 1A Promoter. *Endocrinology* 2005;146:1449-57.
57
58 [46] Gametchu B, Watson CS. Correlation of membrane glucocorticoid receptor levels
59 with glucocorticoid-induced apoptotic competence using mutant leukemic and
60 lymphoma cells lines. *J Cell Biochem* 2002;87:133-46.
61
62
63
64
65

GR Transcription

- 1
2
3
4 [47] Gametchu B, Watson CS, Shih CC, Dashew B. Studies on the arrangement of
5 glucocorticoid receptors in the plasma membrane of S-49 lymphoma cells.
6 *Steroids* 1991;56:411-9.
7
8 [48] Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, et al.
9 Membrane glucocorticoid receptors (mGCR) are expressed in normal human
10 peripheral blood mononuclear cells and up-regulated after in vitro stimulation and
11 in patients with rheumatoid arthritis. *Faseb J* 2004;18:70-80.
12
13 [49] Spies CM, Schaumann DH, Berki T, Mayer K, Jakstadt M, Huscher D, et al.
14 Membrane glucocorticoid receptors are down regulated by glucocorticoids in
15 patients with systemic lupus erythematosus and use a caveolin-1-independent
16 expression pathway. *Ann Rheum Dis* 2006;65:1139-46.
17
18 [50] Diba F, Watson CS, Gametchu B. 5'UTR sequences of the glucocorticoid receptor
19 1A transcript encode a peptide associated with translational regulation of the
20 glucocorticoid receptor. *J Cell Biochem* 2001;81:149-61.
21
22 [51] Bird A. Perceptions of epigenetics. *Nature* 2007;447:396-8.
23
24 [52] Meaney MJ, Szyf M, Seckl JR. Epigenetic mechanisms of perinatal programming
25 of hypothalamic-pituitary-adrenal function and health. *Trends Mol Med*
26 2007;13:269-77.
27
28 [53] Szyf M. The early life environment and the epigenome. *Biochim Biophys Acta*
29 2009;1790:878-85.
30
31 [54] Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev*
32 2002;16:6-21.
33
34 [55] Weaver IC. Epigenetic programming by maternal behavior and pharmacological
35 intervention. Nature versus nurture: let's call the whole thing off. *Epigenetics*
36 2007;2:22-8.
37
38 [56] Weaver IC, D'Alessio AC, Brown SE, Hellstrom IC, Dymov S, Sharma S, et al.
39 The transcription factor nerve growth factor-inducible protein a mediates
40 epigenetic programming: altering epigenetic marks by immediate-early genes. *J*
41 *Neurosci* 2007;27:1756-68.
42
43 [57] Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, et al.
44 Reversal of maternal programming of stress responses in adult offspring through
45 methyl supplementation: altering epigenetic marking later in life. *J Neurosci*
46 2005;25:11045-54.
47
48 [58] Herbeck YE, Gulevich RG, Amelkina OA, Plyusnina IZ, Oskina IN. Conserved
49 methylation of the glucocorticoid receptor gene exon 1(7) promoter in rats
50 subjected to a maternal methyl-supplemented diet. *Int J Dev Neurosci* 2010;28:9-
51 12.
52
53 [59] Daniels WM, Fairbairn LR, van Tilburg G, McEvoy CR, Zigmond MJ, Russell
54 VA, et al. Maternal separation alters nerve growth factor and corticosterone levels
55 but not the DNA methylation status of the exon 1(7) glucocorticoid receptor
56 promoter region. *Metab Brain Dis* 2009;24:615-27.
57
58 [60] McGowan PO, Meaney MJ, Szyf M. Diet and the epigenetic (re)programming of
59 phenotypic differences in behavior. *Brain Res* 2008;1237:12-24.
60
61 [61] Lillycrop KA, Slater-Jefferies JL, Hanson MA, Godfrey KM, Jackson AA,
62 Burdge GC. Induction of altered epigenetic regulation of the hepatic
63 glucocorticoid receptor in the offspring of rats fed a protein-restricted diet during
64
65

GR Transcription

- pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifications. *Br J Nutr* 2007;97:1064-73.
- [62] Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. *Epigenetics* 2008;3:97-106.
- [63] Moser D, Molitor A, Kumsta R, Tatschner T, Riederer P, Meyer J. The glucocorticoid receptor gene exon 1-F promoter is not methylated at the NGFI-A binding site in human hippocampus. *World J Biol Psychiatry* 2007;8:262-8.
- [64] Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, et al. The microRNAs of *Caenorhabditis elegans*. *Genes Dev* 2003;17:991-1008.
- [65] Lee RC, Ambros V. An extensive class of small RNAs in *Caenorhabditis elegans*. *Science* 2001;294:862-4.
- [66] Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet* 2008;9:102-14.
- [67] Bushati N, Cohen SM. microRNA functions. *Annu Rev Cell Dev Biol* 2007;23:175-205.
- [68] Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. *Dev Cell* 2006;11:441-50.
- [69] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116:281-97.
- [70] Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. *Cell* 2005;122:553-63.
- [71] Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. *RNA* 2004;10:1957-66.
- [72] Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. *EMBO J* 2004;23:4051-60.
- [73] Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. *EMBO J* 2002;21:4663-70.
- [74] Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. *Nat Rev Mol Cell Biol* 2005;6:376-85.
- [75] Knight SW, Bass BL. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in *Caenorhabditis elegans*. *Science* 2001;293:2269-71.
- [76] Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. *PLoS Biol* 2005;3:e85.
- [77] Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. *Genes Dev* 2004;18:504-11.
- [78] Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. *Mol Cell* 2007;27:91-105.

GR Transcription

- [79] Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005;120:15-20.
- [80] Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J, Burge CB. Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. *RNA* 2007;13:1894-910.
- [81] Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. *Genes Dev* 2006;20:1885-98.
- [82] de Kloet ER, Fitzsimons CP, Datson NA, Meijer OC, Vreugdenhil E. Glucocorticoid signaling and stress-related limbic susceptibility pathway: about receptors, transcription machinery and microRNA. *Brain Res* 2009;1293:129-41.
- [83] Uchida S, Nishida A, Hara K, Kamemoto T, Suetsugi M, Fujimoto M, et al. Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor. *Eur J Neurosci* 2008;27:2250-61.
- [84] Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. *Proc Natl Acad Sci U S A* 2007;104:9667-72.
- [85] Vreugdenhil E, Verissimo CS, Mariman R, Kamphorst JT, Barbosa JS, Zweers T, et al. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. *Endocrinology* 2009;150:2220-8.
- [86] Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. *Science* 2005;310:1817-21.
- [87] Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. *Mol Cell* 2008;30:460-71.
- [88] Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. *Nat Genet* 2007;39:1278-84.
- [89] Zhang T, Haws P, Wu Q. Multiple variable first exons: a mechanism for cell- and tissue-specific gene regulation. *Genome Res* 2004;14:79-89.
- [90] Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. *Genome Res* 2006;16:55-65.
- [91] Cooper SJ, Trinklein ND, Anton ED, Nguyen L, Myers RM. Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. *Genome Res* 2006;16:1-10.
- [92] Tsuritani K, Irie T, Yamashita R, Sakakibara Y, Wakaguri H, Kanai A, et al. Distinct class of putative "non-conserved" promoters in humans: comparative studies of alternative promoters of human and mouse genes. *Genome Res* 2007;17:1005-14.

GR Transcription

Figure 1: Structure of the GR gene (NR3C1; OMIM + 138040; NR3C1; 5q31-q32), the potential mRNA transcripts and the binding sites within the CpG island.

Panel A The genomic structure of the GR. □ 5' untranslated distal exons; ▤ 5' untranslated CpG island exons; ■ Common exons; ▨ 3' alternatively spliced exons. Panel B shows the potential mRNA transcripts encoding the three GR isoforms: GR α , GR β and GR-P. Panel B shows the location of the known transcription factor binding sites. ▩ IRF 1 and IRF2 (position 1); ▣ c-Myb, c-Ets 1/2 and PU1 (position 4); ▤ Ying Yand 1 (positions 5,6,7 and 25); ■ Glucocorticoid response elements (GRE, positions 2, 3, 8, 21, and 22); ■ Sp1 binding sites (positions 9, 10, 12, 13, 16, 19, 20, 21, and 24); □ NGFIA binding site (position 17); ▨ Glucocorticoid response factor-1 (GRF1, position 18); ▤ Ap-1 (position 15); and ▨ Ap-2 (position 23).

Figure 2: DNA methylation inhibits transcriptional regulation of genes.

A complex of transcription factors (TF), the DNA polymerase (Pol) and co-activators (open circles) normally binds to the GR promoter and thus regulates gene expression.

Epigenetic modifications can lead to methylation of the transcription factor binding site in the GR promoter (full ovals). Therefore binding to the promoter is inhibited and expression of the GR is reduced. Figure from [26] with permission.

Figure 3: Alignment of the rat GR promoter 1₇ and the human GR promoter 1F.

Solid-lined boxes represent known canonical NGFI-A binding sites either in the rat [35, 58, 59] or the human [38, 26, 62, 63] promoter. The broken-lined box in the human 1F promoter represents a hypothetical non-canonical NGFI-A binding site [36].

Figure 4: The GR first exon 1C is rich in potential microRNA binding sites.

MicroRNA binding was predicted based on the probability of interaction by target accessibility (PITA) [88]. Individual binding scores are from the colour scale. Values lower than -11 are normally considered highly relevant.

Table 1. Transcription factor binding sites in the hGR proximal promoter region

Promoter	TF ^a	N°	Sequences	Cell lines / Tissues	Technique ^b	Location ^c		reference
						start	end	
Distal Promoter								
	IRF-1		GTAGAGGCGAATCACTTTCACCTTCTGCTGGG	CEM-C7	FP, EMSA, RG	-34574	-34544	[16, 45]
	IRF-2		GTAGAGGCGAATCACTTTCACCTTCTGCTGGG	CEM-C7, Jurkat	FP, EMSA, RG	-34574	-34544	[16, 45]
	GR-α		TCTGATACCAAATCACTGGACCTTA	CEM-C7	FP, EMSA	-34490	-34466	[18]
	GR-α		GACCGTAAATGCGCATG	CEM-C7, IM-9	FP, EMSA, ChIP	-34436	-34419	[18, 37, 44]
	GR-β		GAGAAGGAGAAAACCTTAGATCTTCTGATACCAA	CEM-C7	FP, EMSA	-34512	-34480	[16]
	c-Myb		ATGTGTCCAACGGAAGCACT	CEM-C7	FP, EMSA, ChIP	-34421	-34402	[18, 44]
	c-Ets 1/2		ATGTGTCCAACGGAAGCACT	CEM-C7	FP, EMSA	-34421	-34402	[18]
	PU.1		ATGTGTCCAACGGAAGCACT	IM-9	EMSA, ChIP	-34421	-34402	[37, 44]
Proximal promoter								
1D	dYY1	1	CCAAGATGG	NIH 3T3, HeLa	FP, D, E	-4807	-4799	[15]
	mYY1	2	CCAAGATGG	NIH 3T3, HeLa	FP, D, E	-4635	-4627	[15]
	pYY1	3	CCAAGATGG	NIH 3T3, HeLa	FP, D, E	-4591	-4583	[15]
	GRE	4	GGCTTCCGGGACGCGCTTCCCAATCGTCTTCAAG	Jurkat, IM-9, CEM-C7	ChIP, E	-4574	-4540	[37]
1J	Sp1	5	GCTGGGGCGGGGCTT	NIH 3T3, HeLa	FP, E	-4250	-4235	[15]
	Sp1	6	TTCGGGGTGGGG	Jurkat, HepG2, HeLa	RG, FP, E	-4011	-3999	[17]
1E	GRE	7	GTGGAAGAAGAGGTCAGGAGTTTC	Jurkat, IM-9, CEM-C7	ChIP, E	-3962	-3939	[37]
1B	Sp1	8	CACATTGGGCGGGAGGGG	Jurkat, HepG2, HeLa	RG, FP, E	-3774	-3757	[17]
	Sp1	9	TTGAACCTGGCAGGCGGGCC	Jurkat, HepG2, HeLa	RG, FP, E	-3750	-3730	[17]
1F	GRE	10	GCACCGTTCCGTGCAACCCCGTAGCCCTTTTGAAGTGACACACT	Jurkat, IM-9, CEM-C7	ChIP, E	-3438	-3393	[37]
	AP-1	11	TGACACA (consensus TGAC/GTCA)	AtT-20, NIH3T3	EMSA	-3401	-3395	[31][14]
	Sp1	12	TGGGCGGGGCGGGAA	HeLa, NIH3T3, CV1, HepG2	RG, FP, EMSA	-3228	-3213	[28]
	NGFIA	13	GGGCGGGGCGG	Rat Hippocampi / HEK293	ChIP	-3227	-3216	[35, 36]
	GRF-1	14	GAAGGAGGTAGCGAGAAAAGAACTGGAGAACTCGGTGG	MCF7, CV-1	EMSA	-3215	-3176	[33, 34]
	Sp1	15	TCTTAACGCGCCCGCAGAGA	HeLa, NIH3T3, CV1, HepG2	RG, FP, EMSA	-3172	-3153	[28]
1C	Sp1	16	GGAGTTGGGGCGGGGGGCG	HeLa, NIH3T3, CV1, HepG2	RG, FP, EMSA	-3107	-3088	[28]
	Sp1	17	GCGCACCGGCGGGGCGGCC	HeLa, NIH3T3, CV1, HepG2	RG, FP, EMSA	-3080	-3061	[28]
	GRE	18	CTGCAGTTGCCAAGCGTCACCAACAGTTGCATCGTTCCCC	Jurkat, IM-9, CEM-C7	ChIP, E	-2971	-2931	[37]
	AP-2	19	CCGCGCGCCCTCGGGCGGGGA	HeLa, NIH3T3, CV1, HepG2	RG, FP, EMSA	-2923	-2901	[28]
	Sp1	20	CGCCGTGGCGCCGCTCCA	HeLa, NIH3T3, CV1, HepG2	RG, FP, EMSA	-2856	-2838	[28]
	iYY1	21	CTCCTCCATTTG	NIH 3T3, HeLa	FP, D, E	-2755	-2743	[28]

^a TF: Transcription Factor

^b RG: reporter gene. FP: DNase protection / DNA footprinting. ChIP: chromatin precipitation. D: deletion analysis. EMSA: electrophoretic mobility shift assay

^c Locations with respect to the ATG start codon in exon 2.


Table 2: Methylation analyses of GR promoter regions

<i>GR promoter</i>	<i>Species</i>	<i>Model</i>	<i>Method</i>	<i>Tissue</i>	<i>Overall methylation levels</i>	<i>CpG specific comments †</i>	<i>Reference</i>
1.7	r. nor.	LG-ABN	colony sequencing	hippocampus	<100%	80-100% at CpG 16-17 in Low LG-ABN 0-10% at CpG 16-17 in High LG-ABN	[35]
1.7	r. nor.	met sup	colony sequencing	hippocampus	<15%	at CpG 16-17	[58]
1.7	r. nor.	maternal sep	direct sequencing	hippocampus	not detected	at CpG 16-17	[59]
1.10	r. nor.	PR diet	MS-PCR	liver	unknown	relative to control PR rats had 30% lower methylation	[61]
1C	r. nor.	HV	methylation sensitive restriction enzyme PCR assay	umbilical blood	unknown	correlation between relative methylation and DNMT1 expression	[61]
1D	h. sap.	HV	colony sequencing	PBMCs	<50%	stochastic and unique	[38]
1E	h. sap.	HV	colony sequencing	PBMCs	>25%	stochastic and unique	[38]
1F	h. sap.	HV	colony sequencing	PBMCs	<10%	at CpG 37-38	[38]
1H	h. sap.	HV	colony sequencing	PBMCs	<75%	stochastic and unique	[38]
1F	h. sap.	Dep	pyrosequencing	cord blood	<7%	<5% at CpG 37-38	[62]
1F	h. sap.	Dep, Al, Park, Dem	MS-PCR	hippocampus	<10%	only 1 subject had visible methylation all other donors unmethylated	[63]
1F	h. sap.	Suicide / abuse	colony sequencing	hippocampus	<40%	0% at CpG 37-38	[36]
1B	h. sap.	MDD	pyrosequencing	hippocampus	0-12%		[26]
1E	h. sap.	MDD	pyrosequencing	hippocampus	4-9%		[26]
1F	h. sap.	MDD	pyrosequencing	hippocampus	0-4%	0-2% at CpG 37-38	[26]
1J	h. sap.	MDD	pyrosequencing	hippocampus	0-7%		[26]

† all CpG numbers as in Figure 3

Abbreviations: r. nor, rattus norvegicus; h. sap, homo sapiens; LG-ABN, licking-grooming and arched-back nursing; met sup, methy-supplemented diet; maternal sep, maternal separation; PR, protein-restricted; HV, healthy volunteer; Dep, depression; Al, Alzheimer's disease; Park, Parkinson's disease; Dem, dementia; MDD, major depressive disorder; MS-PCR, methylation-specific PCR

Figure 1






Figure 2


Rat (1698) 2750 GGCCAGGGCTCTGCGGCACCGTTTCCGTGCCATCCT GTAGCCCTCTG CTAGTGTGACACACTTC¹GC² GCAACTC C³ GCA- 2829
 Human (2494) GGCCGAGACGCTGCGGCACCGTTTCCGTGCAACCC¹²GTAGCCCTTTC¹³GAAGTG--ACACACTTC AC¹⁴GCAACTC¹⁵G GCCC¹⁶

Rat (1795) 2830 GTT GGC⁴ GG- -GC⁵ GC⁶ GGACCAC CCCT GC⁷ GGCTCTGCC⁸ G- ----- ----- ----- GCTG G 2899
 Human (2592) GGC¹⁷GGC¹⁸GGC¹⁹GGC²⁰GC²¹GGGCCAC TCAC²²GC AGCTCAGCC²³GC²⁴GGGAGGC²⁵GCCCC²⁶GGCTCTTGTGGCCC²⁷GCCC²⁸G

Rat (1857) 2900 CTGTCACCC TC GGGGGCTCTGGC TGC -----C¹⁰G ACCCAC¹¹GGG----GC¹²GGGCTCCC¹³GAGC¹⁴GGTTCCA-AGCC T 3002
 Human (2690) CTGTCACCC²⁹GC AGGGGCACTGGC³⁰GGC³¹GCTTGC C³²GCCAAG GGGGAGAGC³³GAGCTCCC³⁴GAGT GGGTCTGGAGCC³⁵G

Rat (1857) C¹⁵GGAGCTGGC¹⁶GGGGGC¹⁷GGAGGGAGCC
 Human (2690) C³⁶GGAGCTGGGC³⁷GGGGGC³⁸GGGAAGGAGGT
 hGR exon 1F -----AGGT

Figure 4: miRNA target prediction on GR exon 1-C1





Glucocorticoid receptor levels are transcriptionally controlled. The variable 5' region produces multiple splice variants coding a single protein, and is regulated by epigenetic methylation and tissue specific transcription factor usage.

